Inês Martins, PhD,  managing science editor—

Commercially insured patients with cold agglutinin disease (CAD) in the U.S. use healthcare resources — hospital admissions, outpatient and emergency room visits, and blood transfusions — more frequently than a matched group of patients without the disease, a large real-world study reports. This utilization was also greater before diagnosis,…

Long-term maintenance treatment with sutimlimab is safe, prevents red blood cell destruction, and increases the amount of hemoglobin in people with cold agglutinin disease (CAD), avoiding the need for blood transfusions. Those findings are detailed in the study “Inhibition of complement C1s in patients with cold…